발생일자 2015.06.03 

사건번호 1:15-cv-00451 

법원국가 UNITED STATES OF AMERICA 

관할법원명 D.C.Delaware(지방법원) 

침해권리 특허 

원고명 Takeda Pharmaceutical Company Limited/ Takeda Pharmaceuticals America, Inc/ Takeda Pharmaceuticals USA, Inc/ Takeda Pharmaceuticals International GmbH/ Orexigen Therapeutics, Inc ( 일본 / 외국기업 )  

피고명 ACTAVIS LABORATORIES FL, Inc./ Actavis, Inc./ Andrx Corporation/ ACTAVIS PHARMA, Inc. ( 미국 / 외국기업 )  

소송유형 침해금지 

[Takeda Pharmaceutical Company Limited et al v. ACTAVIS LABORATORIES FL, Inc. et al] 사건번호 1:15-cv-00451에 따르면 원고 Takeda Pharmaceutical Company Limited/ Takeda Pharmaceuticals America, Inc/ Takeda Pharmaceuticals USA, Inc/ Takeda Pharmaceuticals International GmbH/ Orexigen Therapeutics, Inc는 피고 ACTAVIS LABORATORIES FL, Inc./ Actavis, Inc./ Andrx Corporation/ ACTAVIS PHARMA, Inc.을(를) 상대로 특허 US7375111|US7462626|US8088786|US8318788|US8722085|US8815889|US8916195을(를) 침해하였다는 이유로 미국 델라웨어 지방법원에 소를 제기하였다. 

분쟁결과 분쟁중 

산업분류 화학∙바이오 > 의약품 

계쟁제품 Extended-Release Tablets containing 8 mg of Naltrexone Hydrochloride and 90 mg of Bupropion Hydrochloride, generic version of CONTRAVE 

지재권번호/명칭

US7375111   Compositions for affecting weight loss 

 US7462626   Compositions for affecting weight loss 

 US8088786   Compositions for affecting weight loss 

 US8318788   Compositions for affecting weight loss 

 US8722085   Compositions for affecting weight loss 

 US8815889   Compositions for affecting weight loss 

 US8916195   Compositions for affecting weight loss